Skeletal Dysplasia Market

Mar 2021| MRS117A| Market Research Studies

Report Highlights

The scope of this report covers the different types of Skeletal Dysplasia along with emerging drug therapies for the treatment of skeletal dysplasia. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each type, treatment, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional Skeletal Dysplasia markets; it explains the major market drivers of the Global Skeletal Dysplasia industry, current trends within the industry, major applications and the regional dynamics of the Global Skeletal Dysplasia Market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the Global Skeletal Dysplasia Market. Recent mergers and acquisitions, new product development is also catered in this report.

Report Includes

  • 35 tables and 43 figures
  • An up-to-date analysis of the Global Skeletal Dysplasia Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for Global Skeletal Dysplasia Market, and corresponding market share analysis by type, treatment, end-user, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Skeletal Dysplasia, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new therapies, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the Skeletal Dysplasia Market as compared to overall global economy.
  • Insight into the growth development strategies of major Skeletal Dysplasia manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, Alexion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Merck & Co., Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceuticals Inc., and others.

Summary

Skeletal dysplasia, a rare disease is also commonly known as osteochondrodysplasias. The disease has more than 450 types which alters the development and growth of bones and cartilages. The severity of this disease could be observed in both neonatal as well as adults. But this disorder quite prevalent in children due to inheritance of altered genes from the parents. Some of the symptoms of these disease include stubby fingers, scoliosis, cognitive impairments, missing limbs, joint pain and fractured bones. There are mainly five types of skeletal dysplasia namely, X-linked hypophosphatemia, hypophosphatasia, achondroplasia, fibrodysplasia ossificans progressive and multiple osteochondromas.

It is estimated that the prevalence of skeletal dysplasia is around 7.5 per 100,000 women. People suffering from this disorder have to undergo extensive medical treatment or surgery. Creating awareness among the people about the disease and how to treat the disorder is likely to propel the global skeletal dysplasia market growth. Increasing pipeline product approvals is further going to drive the market during the forecast period.

The Global Skeletal Dysplasia Market was valued at $2.78 billion in 2020 and is expected to witness a steady growth at a CAGR of 5.23%.

  • Table 1 : Global Skeletal Dysplasia Market, Through 2026
  • Table 2 : Global Skeletal Dysplasia, by Type, Through 2026
  • Table 3 : Global Skeletal Dysplasia, by Treatment, Through 2026
  • Table 4 : Global Skeletal Dysplasia, by End-User, Through 2026
  • Table 5 : Global Skeletal Dysplasia, by Region, Through 2026
  • Table 6 : North America Skeletal Dysplasia, by Type, Through 2026
  • Table 7 : North America Skeletal Dysplasia, by Treatment, Through 2026
  • Table 8 : North America Skeletal Dysplasia, by End-User, Through 2026
  • Table 9 : North America Skeletal Dysplasia, by Country, Through 2026
  • Table 10 : Europe Skeletal Dysplasia, by Type, Through 2026
  • Table 11 : Europe Skeletal Dysplasia, by Treatment, Through 2026
  • Table 12 : Europe Skeletal Dysplasia, by End-User, Through 2026
  • Table 13 : Europe Skeletal Dysplasia, by Country, Through 2026
  • Table 14 : Asia-Pacific Skeletal Dysplasia, by Type, Through 2026
  • Table 15 : Asia-Pacific Skeletal Dysplasia, by Treatment, Through 2026
  • Table 16 : Asia-Pacific Skeletal Dysplasia, by End-User, Through 2026
  • Table 17 : Asia-Pacific Skeletal Dysplasia, by Country, Through 2026
  • Table 18 : South America Skeletal Dysplasia, by Type, Through 2026
  • Table 19 : South America Skeletal Dysplasia, by Treatment, Through 2026
  • Table 20 : South America Skeletal Dysplasia, by End-User, Through 2026
  • Table 21 : South America Skeletal Dysplasia, by Country, Through 2026
  • Table 22 : Middle East & Africa Skeletal Dysplasia, by Type, Through 2026
  • Table 23 : Middle East & Africa Skeletal Dysplasia, by Treatment, Through 2026
  • Table 24 : Middle East & Africa Skeletal Dysplasia, by End-User, Through 2026
  • Table 25 : Middle East & Africa Skeletal Dysplasia, by Country, Through 2026
  • Table 26 : Alexion Pharmaceuticals, Inc.: Financial Performance, Through 2020
  • Table 27 : Regeneron Pharmaceuticals, Inc.: Financial Performance, Through 2020
  • Table 28 : Merck & Co.: Financial Performance, Through 2020
  • Table 29 : Ultragenyx Pharmaceutical, Inc.: Financial Performance, Through 2020
  • Table 30 : BioMarin Pharmaceuticals Inc.: Financial Performance, Through 2020
  • Table 31 : Cipla Limited: Financial Performance, Through 2020
  • Table 32 : Ipsen Pharma SA: Financial Performance, Through 2020
  • Table 33 : Invoke SAS: Financial Performance, Through 2020
  • Table 34 : ARUP Laboratories Inc.: Financial Performance, Through 2020
  • Table 35 : Celgene Corporation: Financial Performance, Through 2020
  • Figure 1 : Global Skeletal Dysplasia Market
  • Figure 2 : Global Skeletal Dysplasia, by Value, 2019-2026
  • Figure 3 : Global Skeletal Dysplasia, by Value, by Type, 2019-2026
  • Figure 4 : Global Skeletal Dysplasia, by Value, by Treatment, 2019-2026
  • Figure 5 : Global Skeletal Dysplasia, by Value, by End-User, 2019-2026
  • Figure 6 : Global Skeletal Dysplasia, by Value, by Region, 2020
  • Figure 7 : Global Skeletal Dysplasia, by Value, by Company, 2020
  • Figure 8 : Global Skeletal Dysplasia, Product Map, 2020
  • Figure 9 : North America Skeletal Dysplasia, by Value, 2019-2026
  • Figure 10 : North America Skeletal Dysplasia, by Value, by Type, 2019-2026
  • Figure 11 : North America Skeletal Dysplasia, by Value, by Treatment, 2019-2026
  • Figure 12 : North America Skeletal Dysplasia, by Value, by End-User, 2019-2026
  • Figure 13 : North America Skeletal Dysplasia, by Value, by Country, 2020
  • Figure 14 : Europe Skeletal Dysplasia, by Value, 2019-2026
  • Figure 15 : Europe Skeletal Dysplasia, by Value, by Type, 2019-2026
  • Figure 16 : Europe Skeletal Dysplasia, by Value, by Treatment, 2019-2026
  • Figure 17 : Europe Skeletal Dysplasia, by Value, by End-User, 2019-2026
  • Figure 18 : Europe Skeletal Dysplasia, by Value, by Country, 2020
  • Figure 19 : Asia-Pacific Skeletal Dysplasia, by Value, 2019-2026
  • Figure 20 : Asia-Pacific Skeletal Dysplasia, by Value, by Type, 2019-2026
  • Figure 21 : Asia-Pacific Skeletal Dysplasia, by Value, by Treatment, 2019-2026
  • Figure 22 : Asia-Pacific Skeletal Dysplasia, by Value, by End-User, 2019-2026
  • Figure 23 : Asia-Pacific Skeletal Dysplasia, by Value, by Country, 2020
  • Figure 24 : South America Skeletal Dysplasia, by Value, 2019-2026
  • Figure 25 : South America Skeletal Dysplasia, by Value, by Type, 2019-2026
  • Figure 26 : South America Skeletal Dysplasia, by Value, by Treatment, 2019-2026
  • Figure 27 : South America Skeletal Dysplasia, by Value, by End-User, 2019-2026
  • Figure 28 : South America Skeletal Dysplasia, by Value, by Country, 2020
  • Figure 29 : Middle East & Africa Skeletal Dysplasia, by Value, 2019-2026
  • Figure 30 : Middle East & Africa Skeletal Dysplasia, by Value, by Type, 2019-2026
  • Figure 31 : Middle East & Africa Skeletal Dysplasia, by Value, by Treatment, 2019-2026
  • Figure 32 : Middle East & Africa Skeletal Dysplasia, by Value, by End-User, 2019-2026
  • Figure 33 : Middle East & Africa Skeletal Dysplasia, by Value, by Country, 2020
  • Figure 34 : Alexion Pharmaceuticals, Inc.: Revenue Share, 2020
  • Figure 35 : Regeneron Pharmaceuticals, Inc.: Revenue Share, 2020
  • Figure 36 : Merck & Co.: Revenue Share, 2020
  • Figure 37 : Ultragenyx Pharmaceutical, Inc.: Revenue Share, 2020
  • Figure 38 : BioMarin Pharmaceuticals Inc.: Revenue Share, 2020
  • Figure 39 : Cipla Limited: Revenue Share, 2020
  • Figure 40 : Ipsen Pharma SA: Revenue Share, 2020
  • Figure 41 : Invoke SAS: Revenue Share, 2020s
  • Figure 42 : ARUP Laboratories Inc.: Revenue Share, 2020
  • Figure 43 : Celgene Corporation: Revenue Share, 2020

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report